

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ira H. Pastan et al.**Application No.:** 10/031,158**Filed:** January 11, 2002**Confirmation No.:** 8170**For:** T-CELL RECEPTOR Y ALTERNATE
READING FRAME PROTEIN, (TARP)
AND USES THEREOF**Examiner:** Stephen L. Rawlings, Ph.D.**Art Unit:** 1641**Attorney Reference No.:** 4239-61854-01**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)Date Mailed November 11, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

11/17/2004 EHAILE1 00000023 10031158

03 FC:1806

180.00 0P

Submitted herewith is a check for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).


Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 228-9446

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Attorney Docket Number	4239-61854-01
				Application Number	10/031,158
				Filing Date	January 11, 2002
				First Named Inventor	Ira H. Pastan
				Art Unit	1641
				Examiner Name	Stephen L. Rawlings, Ph.D.
U.S. PATENT DOCUMENTS					
Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee	
FOREIGN PATENT DOCUMENTS					
Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS			
		Oh et al., <i>Cancer Research</i> 64:2610-2618, 2004			
		Wolfgang et al., <i>Cancer Research</i> 61:8122-8126, 2001			
		GENBANK® Accession No. AAG29337			
		GENBANK® Accession No. AI557112			
		GENBANK® Accession No. CAA51166			
		GENBANK® Accession No. M27334			
		GENBANK® Accession No. X72500			

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	